论文部分内容阅读
目的探讨原发性肝癌微创介入治疗术后乙型肝炎病毒(HBV)再激活的主要影响因素。方法收集50例HBV相关肝癌患者作为研究对象,以性别、年龄、抗病毒治疗、血常规、肝功能、肿瘤标志物甲胎蛋白(AFP)、微创治疗方法等作为研究因素,以是否引起HBV再激活作为因变量进行Logistic逐步回归分析。结果单因素分析显示,术前HBV DNA浓度、门脉癌栓、肿瘤大小、术前抗病毒治疗等均为影响因素(P<0.1)。经Logistic逐步回归分析提示,影响HBV再激活的影响因素涉及肿瘤大小、抗病毒治疗等,其中术前规范抗病毒治疗是保护因素,肿瘤直径>5 cm是HBV再激活的危险因素。结论 HBV相关原发性肝癌微创介入治疗后HBV再激活与肿瘤直径大小及是否术前抗病毒治疗等因素有关。肝癌肿瘤直径较大的患者,要重点监测并积极进行强效抗病毒治疗,以防HBV再激活。
Objective To investigate the main influencing factors of hepatitis B virus (HBV) reactivation after minimally invasive interventional treatment of primary liver cancer. Methods Fifty patients with HBV-related hepatocellular carcinoma (HCC) were enrolled in this study. Gender, age, antiviral therapy, blood routine, liver function, tumor marker AFP and minimally invasive treatment were used as researching factors to determine if HBV Reactivation as a dependent variable Logistic stepwise regression analysis. Results Univariate analysis showed that preoperative HBV DNA concentration, portal vein tumor thrombus, tumor size and preoperative antiviral therapy were the influencing factors (P <0.1). Logistic stepwise regression analysis showed that the influencing factors of HBV reactivation involved tumor size and antiviral therapy. The preoperative standard antiviral therapy was the protective factor. The tumor diameter> 5 cm was a risk factor for HBV reactivation. Conclusions HBV reactivation after minimally invasive interventional therapy of HBV-related primary hepatocellular carcinoma is related to tumor diameter, preoperative antiviral therapy and other factors. Patients with a larger diameter of liver cancer should focus on monitoring and aggressive potent antiviral therapy to prevent HBV reactivation.